About Verve Therapeutics
Verve Therapeutics is a Healthcare company based in Cambridge (United States) founded in 2018 by J Keith Joung, Issi Rozen, and Burt Adelman, and was acquired by Lilly in June 2025. Gene-editing therapies for coronary artery disease are developed. It operates on a HealthTech model. Verve Therapeutics has raised $215.5 million across 3 funding rounds from investors including Lilly, Citadel and Janus Henderson Investors. The company has 255 employees. Its website vervetx.com draws about 13 thousand monthly visits. Verve Therapeutics offers products and services including VERVE-102 and VERVE-201. Its focus areas include Biotechnology and Gene Therapy. Its legal entity is Verve Therapeutics, Inc. Its competitors include Moderna, BridgeBio and Spark Therapeutics; 3 of its 3 listed competitors have raised funding.
Company details
Verve Therapeutics is dedicated to combating cardiovascular disease (CVD), the leading cause of death worldwide, through innovative single-course gene editing medicines. Solutions are developed to inactivate specific genes in the liver that contribute to CVD risk. The pipeline includes programs like VERVE-102 and VERVE-201, targeting conditions such as heterozygous familial hypercholesterolemia (HeFH) and premature coronary artery disease. Advances in human genetics and gene editing technologies are leveraged to transform the treatment paradigm for hundreds of millions affected by atherosclerotic cardiovascular disease (ASCVD).
- Headquarters Cambridge, United States
- Employees 255
- Founders J Keith Joung, Issi Rozen, Burt Adelman
- Stage Acquired
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Phone•••• ••••
- Website vervetx.com
- Social LinkedIn X
- Acquired by Lilly (Jun 2025)
- Legal Name Verve Therapeutics, Inc.
Products & Services of Verve Therapeutics
Verve Therapeutics offers a comprehensive portfolio of products and services, including VERVE-102 and VERVE-201.
Gene editing therapy targeting PCSK9 for LDL-C reduction.
Gene editing solution addressing cardiovascular disease risk factors.
Funding Insights of Verve Therapeutics
Verve Therapeutics has successfully raised a total of $215.5M across 3 strategic funding rounds. The most recent funding activity was a Series B round of $94 million completed in January 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $215.5M
- Total Rounds 3
- Last Round Series B — $94M
- First Round $58.5M
(May 2019)
- Investors Count 14
All 3 funding rounds of Verve Therapeutics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jan 2021 | $94M | Series B | – | Wellington, Casdin Capital | |
| Jun 2020 | $63M | Series A | – | Google Ventures | |
| May 2019 | $58.5M | Series A | – | Google Ventures |
15 investors in total: 15 institutional.
Investors in Verve Therapeutics
Verve Therapeutics has secured backing from 15 investors, including institutional and venture fund investors. Prominent investors backing the company include Lilly, Citadel and Janus Henderson Investors.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Investing in Life Sciences sectors like Healthcare and Biotechnology. | casdincapital.com | |||
Multiple sectors are targeted for venture capital investments. | 1934 | janushenderson.com | London, United Kingdom | |
Private equity and venture capital fund focused on the healthcare sector | novoholdings.dk | Hellerup, Denmark | ||
Private equity fund focused on the biotechnology sector | logoscapital.com | San Francisco, United States | ||
Early-stage and late-stage biotech and finance companies are funded. | rockspringscapital.com | Baltimore, United States | ||
Corporate backed venture capital fund investing in multiple sectors | gv.com | Mountain View, United States | ||
Early-stage tech and life sciences focused VC firm investing primarily in the US | biomaticscapital.com | Seattle, United States | ||
Venture capital firm focused on life science companies | 1986 | archventure.com | Chicago, United States | |
Investments in life sciences, technology, healthtech, and crypto sectors from global locations. | fprimecapital.com | |||
Diversified investment management services are provided to institutional clients. | wellington.com | Boston, United States |
Investor details for Verve Therapeutics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Verve Therapeutics
110 people are tracked at Verve Therapeutics (35 in leadership, 9 in board & advisors, 66 in team); the tracked headcount is 255.
| Name | Role | Group |
|---|---|---|
J Keith Joung | Co-Founder | Leadership |
Issi Rozen | Co-Founder | Leadership |
Burt Adelman | Co-Founder & Chairman | Leadership |
Dayna Lesueur | Associate Director, Regulatory Affairs | Leadership |
Sekar Kathiresan | Co-Founder & CEO | Leadership |
Kallanthottathil G. Rajeev | VP, CMC | Leadership |
David Bassen | Associate Director, Pharmacokinetics & Biodistribution | Leadership |
Joe Biedenkapp | VP, Editing Development | Leadership |
William F McDonald | Vice President/ Head Of Manufacturing And Supply | Leadership |
Richard Lee | Senior Director, Preclinical Pharmacology & Translational Medicine | Leadership |
Jason Politi | Chief Technical Officer | Leadership |
Pratik Randeria | Director, Process Development | Leadership |
Yasser El-Gamal | VP, Legal Affairs & Chief Intellectual Property Counsel | Leadership |
Lisa McCurley | Director, Regulatory Operations | Leadership |
Yuri Matsumoto | Associate Director, Bioanalysis | Leadership |
Allen Barrett | Director, Corporate Counsel | Leadership |
Pete Cotter | Associate Director, Analytical Development | Leadership |
James Madsen | Director, Mass Spectrometry | Leadership |
Christopher J. Cheng | VP, Process Development & RNA Technology | Leadership |
Aaron Beach | Director, Analytical Development | Leadership |
90 more people are available in the full profile.
Complete people profiles for Verve Therapeutics
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Verve Therapeutics
5 dated milestones of Verve Therapeutics across 7 years, from founding to its latest funding, stage changes and deals.
- Founded Verve Therapeutics is founded.
- Funding First funding round of $58.5M.
- Funding Latest funding round, Series B, of $94.0M.
- IPO Lists on the stock exchange (IPO).
- Exit Acquired by Lilly.
Competitors of Verve Therapeutics
Verve Therapeutics has 3 listed competitors in our database, 3 of them funded. They include Moderna, BridgeBio and Spark Therapeutics.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| modernatx.com | 2010 | Cambridge, United States | $2.78B | 1,312 | mRNA-based therapeutics for diseases including cancer and infections are developed. | |
| bridgebio.com | 2015 | Palo Alto, United States | $434.2M | Therapeutics for genetic diseases are developed through targeted interventions. | ||
| sparktx.com | 2013 | Philadelphia, United States | $82.8M | 822 | Gene therapies for rare diseases including retinal dystrophies are developed. |
Detailed competitors of Verve Therapeutics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Verve Therapeutics
The website of Verve Therapeutics (vervetx.com) receives about 12.5K visits a month and ranks #1,896,748 among all websites worldwide, #2,589 in Biotechnology and Pharmaceuticals.
- Monthly visits12.5K
▼ 16.2% vs previous month
- Unique visitors4.7K
per month
- Global rank#1,896,748
among all websites
- Category rank#2,589
Health · Biotechnology and Pharmaceuticals
- Bounce rate57%
- Pages per visit1.3
- Average visit19 sec
- DevicesDesktop 51% · Mobile 49%
Websites whose visitors overlap most with Verve Therapeutics. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| fiercebiotech.com | 100% | 858.3K | #81,022 | View details |
Top companies in Genomics & Gene Therapy Platforms
3 companies that operate in the same segment as Verve Therapeutics (Genomics & Gene Therapy Platforms) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Verve Therapeutics
Complete news archive for Verve Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Verve Therapeutics
Verve Therapeutics was founded in 2018 and raised its 1st funding round 1 year after it was founded.
Verve Therapeutics is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.
Verve Therapeutics is a funded company, having raised a total of $215.5M across 3 funding rounds to date. The company's 1st funding round was a Series A of $58.5M, raised on May 2019.
Verve Therapeutics has 255 employees.
Verve Therapeutics is dedicated to combating cardiovascular disease (CVD), the leading cause of death worldwide, through innovative single-course gene editing medicines. Solutions are developed to inactivate specific genes in the liver that contribute to CVD risk. The pipeline includes programs like VERVE-102 and VERVE-201, targeting conditions such as heterozygous familial hypercholesterolemia (HeFH) and premature coronary artery disease. Advances in human genetics and gene editing technologies are leveraged to transform the treatment paradigm for hundreds of millions affected by atherosclerotic cardiovascular disease (ASCVD).
Verve Therapeutics's top competitors include Moderna, Spark Therapeutics and BridgeBio.
Verve Therapeutics offers VERVE-102 and VERVE-201.
Verve Therapeutics has 15 investors. Key investors include Lilly, Citadel, Janus Henderson Investors, RA Capital, and Arch Venture Partners.
Verve Therapeutics operates through Verve Therapeutics, Inc..
Yes. Verve Therapeutics was acquired by Lilly in June 2025.